These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37997571)

  • 41. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
    El-Galaly TC; Cheah CY; Bendtsen MD; Nowakowski GS; Kansara R; Savage KJ; Connors JM; Sehn LH; Goldschmidt N; Shaulov A; Farooq U; Link BK; Ferreri AJM; Calimeri T; Cecchetti C; Dann EJ; Thompson CA; Inbar T; Maurer MJ; Gade IL; Juul MB; Hansen JW; Holmberg S; Larsen TS; Cordua S; Mikhaeel NG; Hutchings M; Seymour JF; Clausen MR; Smith D; Opat S; Gilbertson M; Thanarajasingam G; Villa D
    Eur J Cancer; 2018 Apr; 93():57-68. PubMed ID: 29477102
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R
    Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.
    Gregory G; Arumugaswamy A; Leung T; Chan KL; Abikhair M; Tam C; Bajel A; Cher L; Grigg A; Ritchie D; Opat S
    Neuro Oncol; 2013 Aug; 15(8):1068-73. PubMed ID: 23502429
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.
    Villa D; Connors JM; Shenkier TN; Gascoyne RD; Sehn LH; Savage KJ
    Ann Oncol; 2010 May; 21(5):1046-52. PubMed ID: 19861575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era.
    Sert F; Kamer S; Saydam G; Anacak Y
    J Cancer Res Ther; 2018; 14(6):1397-1402. PubMed ID: 30488862
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
    Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab era.
    Vassilakopoulos TP; Panitsas F; Mellios Z; Apostolidis J; Michael M; Gurion R; Ferhanoglu B; Hatzimichael E; Karakatsanis S; Dimou M; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Giatra H; Kanellias N; Sayyed A; Tadmor T; Akay OM; Angelopoulou MK; Horowitz N; Bakiri M; Pangalis GA; Panayiotidis P; Papageorgiou SG
    Hematol Oncol; 2023 Feb; 41(1):97-107. PubMed ID: 36314897
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.
    Eyre TA; Djebbari F; Kirkwood AA; Collins GP
    Haematologica; 2020 Jul; 105(7):1914-1924. PubMed ID: 31488560
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
    Zhang J; Chen B; Xu X
    Leuk Lymphoma; 2014 Mar; 55(3):509-14. PubMed ID: 23741977
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.
    Perry C; Ben Barouch S; Goldschmidt N; Sarid N; Herishanu Y; Shvidel L; Bairey O; Lavi N; Horowitz N; Avigdor A; Lebel E; Sofer O; Ram R; Avivi I
    Am J Hematol; 2019 Sep; 94(9):992-1001. PubMed ID: 31211434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
    Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
    Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture.
    Kawano N; Ochiai H; Yoshida S; Yamashita K; Shide K; Shimoda H; Hidaka T; Kubuki Y; Katayose K; Toyama T; Kawano H; Matsuoka H; Ishizaki J; Maeda K; Satou S; Yano T; Yamaguchi K; Takenaka K; Shimao Y; Oshima K; Ueda A; Shimoda K
    Int J Clin Oncol; 2012 Aug; 17(4):336-40. PubMed ID: 21904968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the Rituximab era: a SEER database analysis.
    Liu PP; Wang KF; Jin JT; Bi XW; Sun P; Wang Y; Yang H; Li ZM; Jiang WQ; Xia Y
    Cancer Med; 2018 May; 7(5):1845-1851. PubMed ID: 29624913
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis--A Systematic Review of Prospective Studies.
    Ghose A; Elias HK; Guha G; Yellu M; Kundu R; Latif T
    Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):451-7. PubMed ID: 25816933
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CNS prophylaxis in aggressive B-cell lymphoma.
    Wilson MR; Bobillo S; Cwynarski K
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):138-145. PubMed ID: 36485105
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study.
    Miyazaki K; Asano N; Yamada T; Miyawaki K; Sakai R; Igarashi T; Nishikori M; Ohata K; Sunami K; Yoshida I; Yamamoto G; Takahashi N; Okamoto M; Yano H; Nishimura Y; Tamaru S; Nishikawa M; Izutsu K; Kinoshita T; Suzumiya J; Ohshima K; Kato K; Katayama N; Yamaguchi M
    Haematologica; 2020 Sep; 105(9):2308-2315. PubMed ID: 33054055
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma].
    Wang Y; Shi ZY; Shi Q; Wang S; Zhang MC; Shen R; He Y; Qiu HL; Yi HM; Dong L; Wang L; Cheng S; Xu PP; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):321-327. PubMed ID: 37357002
    [No Abstract]   [Full Text] [Related]  

  • 58. Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
    Goldschmidt N; Horowitz NA; Heffes V; Darawshy F; Mashiach T; Shaulov A; Gatt ME; Dann EJ
    Leuk Lymphoma; 2019 Aug; 60(8):1890-1898. PubMed ID: 30689468
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
    Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
    Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.